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Ex vivo experiments have strangely shown that inhibition or stimulation of NADmetabolism can be neuropro-
tective. In this issue of Cell Metabolism, Brown et al. (2014) demonstrate that cochlear NAD is diminished by
deafening noise but protected by nicotinamide riboside or WldS mutation. Hearing protection by nicotin-
amide riboside depends on Sirt3.The Wallerian degeneration slow (WldS)
mouse has been trying to tell us something
aboutneurodegeneration forover20years,
but it has been difficult for us to hear an un-
equivocal message. Wallerian degenera-
tion is the active process by which axons
degenerate distal to injuries causedby cut-
ting or crushing nerve fibers. Wallerian-
related degeneration is found in multiple
diseasesand conditions, including chemo-
therapy-induced nerve damage, at least in
nerve cell culture.Because theWldSmuta-
tion allows mice and nerves analyzed
ex vivo to resist these insults, we’d like to
know how it does this and how we can
exploit this information toopposeneurode-
generation (Coleman and Freeman, 2010).
New data indicate that nicotinamide ribo-
side (NR) protects mice from noise-
induced hearing loss (Brown et al., 2014).
This discovery is mechanistically insightful
and translationally promising.
WldS acts as a dominant trait consisting
of triplicationof a fusionbetween theN ter-
minus of polyubiquitylation factor Ube4b
and the full-length of NAD biosynthetic
enzyme NMN adenylyltransferase 1
(Nmnat1) (Coleman and Freeman, 2010).
When WldS was cloned, there was
an impression that NAD biosynthesis is
ubiquitous and unregulated, suggesting
the possibility that WldS functions as
a dominant-negative Ube4b. However,
neuronal overexpression of Nmnat1 pro-
tects cultured neurons from vincristine-
induced axonapathy (Araki et al., 2004).
Moreover, addition of any of three NAD
precursor vitamins protects cultured
neurons against axonopathy. Two of three
vitamins required concomitant introduc-
tion of a biosynthetic gene, while NR,
a recently discovered NAD precursor
vitamin (Bieganowski and Brenner,
2004), protected because the NR kinase926 Cell Metabolism 20, December 2, 2014 ª2 gene is transcriptionally upregulated by
nerve damage (Sasaki et al., 2006).
These results emphasized the potential
for dysregulation and modulation of NAD
in pathophysiology because cellular dam-
age can induce activities such as poly
(ADP-ribose) polymerase (PARP), which
degrades nucleocytoplasmic NAD (Be-
lenky et al., 2007). Indeed, the length and
specialized structures inherent in sensory
and peripheral neurons may render them
particularly sensitive to NAD-dependent
bioenergetics. If this is the case, it might
follow that PARP activation—secondary
to reactive oxygen species (ROS) pro-
duced in response to drugs or elevated
glucose metabolism—is a central player
in chemotherapy-induced and diabetic
peripheral neuropathies. Because NAD
salvage from NR is inducible by damage
(Sasaki et al., 2006), NR has strong poten-
tial as a neuroprotective agent.
The WldS story became more compli-
cated with conflicting claims about the
role ofNmnat isozymes in neuroprotection.
Nmnat1 is reported to be mostly nuclear,
while Nmnat2 is associated with the cyto-
solic face of Golgi membranes, and
Nmnat3 is reported to be inside the mito-
chondrial matrix (Coleman and Freeman,
2010). Nmnat1 loss-of-function mutations
cause retinal neurodegeneration, and
Nmnat2 knockdown in cultured neurons
promotes neurite degeneration, while
Nmnat3 overexpression hasWldS-like ac-
tivity. However, in some systems, overex-
pression of Nmnat active site mutants
also provided WldS-like activity (Coleman
and Freeman, 2010). In such systems, the
potential for NAD-dependent protection
was discounted andWldSwas interpreted
as a protein that protects against nerve
damage by relief of proteotoxicity (Zhai
et al., 2008). The site of action of WldS is2014 Elsevier Inc.also controversial. Some studies conclude
that mitochondrial localization is required
for neuroprotection, while other studies
claim to exclude mitochondria as sites of
WldS-dependent neuroprotection.
Pharmacological experiments did not
settle these issues. In one system,
FK866, a specific inhibitor of NAD bio-
synthetic enzyme nicotinamide phos-
poribosyltransferase, induces atrophy in
cultured neurons (Wang and He, 2009).
In another, FK866 protects transected
axons from degeneration, leading to the
conclusion that WldS uses its active site
not to make NAD but to rid neurons of
NMN, a putative cell death signal that
would arise when the unstable Nmnat2
protein falls below a critical concentration
in the distal axon (Di Stefano et al., 2014).
In the absence of an in vivo test, current
models are starkly different. Does NAD
protect from Wallerian degeneration
because axonal and/or mitochondrial
NAD are under attack by nerve damage
(Araki et al., 2004; Sasaki et al., 2006;
Wang and He, 2009), or does NMN signal
damaged nerves to die back because
the axon has determined that Nmnat2
transport has ceased (Di Stefano et al.,
2014)? The former model predicts that
NR would be neuroprotective in vivo while
the latter model predicts that NR-depen-
dent formation of NMN would accelerate
nerve loss.Models that rejectNADbiosyn-
thesis (Zhai et al., 2008) would be embold-
ened by a finding that NR is inert in vivo.
The results were remarkably clean. In
mice, loud noises sufficient to produce
temporary loss of hearing drove down
cochlear NAD. The WldS mutation or NR
prevented loss of NAD and maintained
good hearing. Moreover, NR-dependent
protection depended on the mitochon-
drial NAD-dependent protein lysine
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of this is wonderful news for the future of
NR and NAD-boosting neurotherapeutic
approaches. Because Sirt3 was required
for NR function, it stands to reason that
NR increased mitochondrial NAD synthe-
sis. However, these results do not rule out
WldS functions in the axonal cytosol nor
exclude a role for axonal NMN as a
degenerative signal.
The way to synthesize the concepts of
NMN as neurotoxic and NAD as neuro-
protective is to appreciate that cytosolic
NAD is required to generate ATP for
anterograde vesicular transport. Indeed,
increasing evidence indicates that glyco-
lytic enzymes and Nmnat2 are vesicle-
associated, which allows such organelles
to traverse the length of neurons with
‘‘on-board’’ ATP production (Zala et al.,
2013). Because Nmnat2 is unstable,
depletion of the ability to convert NMN to
NAD could limit glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) and dam-
age neuronal energetics because the pre-
paratory phase of glycolysis (upstream of
GAPDH) costs two ATP per input glucose.
Without an ATP payoff and the resulting
production of cytosolic GTP, the ability to
translate and transport new Nmnat2 and
other proteins would be greatly compro-mised, and NMN accumulation could be
readbysuchdamagedneuronsasasignal
to die back. In thepresenceofWldSorNR,
I predict that cytosolic and mitochondrial
NAD formation are improved, with axonal
NAD preserving transport of GAPDH,
Nmnat2, and other molecules along
lengthy microtubules. So long as antero-
grade transport is functioning, there
should not be accumulation of NMN or a
degenerative signal produced by NMN.
The most recent result (Brown et al.,
2014) also demands a role for mitochon-
drial NAD, which is thought to be pro-
duced from mitochondrial transport of
cytosolic NMN. Why Sirt3 would need
to deacetylate mitochondrial proteins
to prevent neurodegeneration is not
known, though mitochondrial proteins
are frequently inactivated by acetylation.
Future experiments are expected to clarify
whether loud noise inducesPARP in away
that makes GAPDH require increased
axonal synthesis of NAD, whether noise
alters mitochondrial metabolism in a
manner that drives acetyl modifications
onto protein targets, to what degree ROS
damage is attenuated by provision of
NR, and whether NR can be used to pre-
vent or treat additional neurodegenerative
diseases and conditions.Cell Metabolism 20,REFERENCES
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Myriad strategies have been explored to compensate for the lack of dystrophin or to skip mutations that
cause the lethal disease Duchenne muscular dystrophy (DMD). A new study shows that gene editing strate-
gies used by bacteria can be applied in zygotes of a mouse model of DMD to correct the genetic defect that
causes muscular dystrophy (Long et al., 2014).Duchenne muscular dystrophy (DMD) is
a lethal, X-linked recessive disease
affecting approximately 1 of 3,500 bornmales. Upon discovery that DMD is a
monogenic disease caused by mutations
of the dystrophin gene, hopes were highthat targeting thewild-typegene todystro-
phicmuscle would provide a cure. In inter-
vening decades, an impressive array ofDecember 2, 2014 ª2014 Elsevier Inc. 927
